Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 16/20 | 0.67 |
| ▸ | SLC6A3 | Q01959 | 15/20 | 0.67 |
| ▸ | SLC6A2 | P23975 | 14/20 | 0.67 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.62 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | TACR1 | P25103 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9026645 | 0.96 | SLC6A4 (0.68) | SLC6A4SLC6A3SLC6A2CYP2D6TACR1 | |
| SCHEMBL6993234 | 0.92 | SLC6A4 (0.56) | SLC6A4SLC6A3SLC6A2CYP2D6KCNH2 | |
| Hydrochloric Acid SCHEMBL7000511 | 0.90 | SLC6A4 (0.54) | SLC6A4SLC6A3SLC6A2CYP2D6KCNH2 | |
| SCHEMBL9026651 | 0.89 | SLC6A4 (0.53) | SLC6A4SLC6A3SLC6A2CYP2D6TACR1 | |
| SCHEMBL3466107 | 0.88 | SLC6A4 (0.79) | SLC6A4SLC6A3SLC6A2CYP2D6 | |
| SCHEMBL13345103 | 0.88 | SLC6A4 (0.79) | SLC6A4SLC6A3SLC6A2CYP2D6 | |
| SCHEMBL13345734 | 0.82 | SLC6A4 (0.62) | SLC6A4SLC6A3SLC6A2CYP2D6TACR1 | |
| SCHEMBL1986782 | 0.81 | SLC6A4 (0.72) | SLC6A4SLC6A3SLC6A2CYP2D6TACR1 | |
| SCHEMBL1986784 | 0.81 | SLC6A4 (0.72) | SLC6A4SLC6A3SLC6A2CYP2D6TACR1 | |
| SCHEMBL1981733 | 0.81 | SLC6A4 (1.00) | SLC6A4SLC6A3SLC6A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0714891-A1 | Heterocyclic tachykinin receptor antagonists | ELI LILLY AND COMPANY (US) | 1996-06-05 | — | — | EP | disclosed |